Other equities research analysts have also recently issued reports about the stock. Morgan Stanley set a €105.00 ($122.09) price target on shares of Sanofi and gave the stock a buy rating in a research note on Tuesday, February 4th. Jefferies Financial Group set a €110.00 ($127.91) target price on shares of Sanofi and gave the stock a buy rating in a research report on Thursday, February 6th. Deutsche Bank set a €92.00 ($106.98) target price on shares of Sanofi and gave the stock a buy rating in a research report on Wednesday, December 11th. Kepler Capital Markets set a €99.00 ($115.12) target price on shares of Sanofi and gave the stock a buy rating in a research report on Monday, February 10th. Finally, Sanford C. Bernstein set a €100.00 ($116.28) target price on shares of Sanofi and gave the stock a buy rating in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of €98.35 ($114.36).
Sanofi stock opened at €92.24 ($107.26) on Wednesday. Sanofi has a 12-month low of €63.09 ($73.36) and a 12-month high of €92.97 ($108.10). The firm’s 50-day moving average is €90.73 and its two-hundred day moving average is €83.67.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Further Reading: Gross Domestic Product (GDP)
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.